StockData
Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc (IONS) stock

IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/304% below fair value
$26.58−0.64 (-2.35%)

Close on Nov 20, 2026Market cap $4.42BP/E –Yield –

Ionis Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Ionis Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$560.84M. For fiscal 2025 it was -$320.03M. The highest annual figure on record is $589.30M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$320.03M–
FY2024Dec 31, 2024-$546.23M–
FY2023Dec 31, 2023-$331.32M–
FY2022Dec 31, 2022-$290.09M-1639.4%
FY2021Dec 31, 2021$18.84M+2340.9%
FY2020Dec 31, 2020$772.00K-99.8%
FY2019Dec 31, 2019$314.72M-46.6%
FY2018Dec 31, 2018$589.30M+322.8%
FY2017Dec 31, 2017$139.39M–
FY2016Dec 31, 2016-$119.21M-987.5%
FY2015Dec 31, 2015$13.43M–
FY2014Dec 31, 2014-$1.23M-102.0%
FY2013Dec 31, 2013$61.94M+15502.3%
FY2012Dec 31, 2012$397.00K–
FY2011Dec 31, 2011-$122.13M–
FY2010Dec 31, 2010-$76.83M–
FY2009Dec 31, 2009-$121.86M-161.4%
FY2008Dec 31, 2008$198.37M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$549.45M+295.2%
Q1 FY2026Mar 31, 2026-$814.58M–
Q4 FY2025Dec 31, 2025-$159.00M–
Q3 FY2025Sep 30, 2025-$136.71M–
Q2 FY2025Jun 30, 2025$139.03M–
Q1 FY2025Mar 31, 2025-$163.35M–
Q4 FY2024Dec 31, 2024-$141.64M-520.5%
Q3 FY2024Sep 30, 2024-$124.05M–
Q2 FY2024Jun 30, 2024-$126.11M–
Q1 FY2024Mar 31, 2024-$154.43M–
Q4 FY2023Dec 31, 2023$33.68M–
Q3 FY2023Sep 30, 2023-$111.16M–
Q2 FY2023Jun 30, 2023-$109.38M–
Q1 FY2023Mar 31, 2023-$144.46M–
Q4 FY2022Dec 31, 2022-$204.33M-201.6%
Q3 FY2022Sep 30, 2022-$29.97M–
Q2 FY2022Jun 30, 2022-$21.43M–
Q1 FY2022Mar 31, 2022-$34.36M–
Q4 FY2021Dec 31, 2021$201.19M+116.7%
Q3 FY2021Sep 30, 2021-$58.90M–
Q2 FY2021Jun 30, 2021-$67.01M–
Q1 FY2021Mar 31, 2021-$56.43M–
Q4 FY2020Dec 31, 2020$92.83M-65.6%
Q3 FY2020Sep 30, 2020-$22.07M–
Q2 FY2020Jun 30, 2020-$53.32M–
Q1 FY2020Mar 31, 2020-$16.67M-116.0%
Q4 FY2019Dec 31, 2019$270.08M+136.7%
Q3 FY2019Sep 30, 2019-$28.71M–
Q2 FY2019Jun 30, 2019-$31.13M-106.3%
Q1 FY2019Mar 31, 2019$104.48M+865.4%
Q4 FY2018Dec 31, 2018$114.12M+840.1%
Q3 FY2018Sep 30, 2018-$29.25M-350.6%
Q2 FY2018Jun 30, 2018$493.60M–
Q1 FY2018Mar 31, 2018$10.82M-90.9%
Q4 FY2017Dec 31, 2017$12.14M–
Q3 FY2017Sep 30, 2017$11.67M-49.8%
Q2 FY2017Jun 30, 2017-$3.85M–
Q1 FY2017Mar 31, 2017$119.43M–
Q4 FY2016Dec 31, 2016-$29.63M–
Q3 FY2016Sep 30, 2016$23.24M–

More Ionis Pharmaceuticals figures

See a number that looks wrong?